Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06978699RecruitingPhase 2
Testing XH-S003 for people with PNH
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
TianjinAges 18 years+ - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+ - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT07063888RecruitingPhase 2
Chemoradiation after surgery for bile duct cancer
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
BeijingAges 18–80 - NCT07057791RecruitingPhase 2
Chemo plus immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Miami, FloridaAges 18 years+ - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT07038005RecruitingPhase 1
Testing a new drug SPGL008 for advanced solid tumors
This trial tests an experimental drug called SPGL008 in people with advanced solid tumors that have spread or cannot be removed. It is a first-in-human study to learn about safety, dosing, and how the drug works.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07043946RecruitingPhase 1/Phase 2
Budoprutug for immune thrombocytopenia
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
PlovdivAges 18 years+ - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75 - NCT07029932RecruitingPhase 1
Testing the safety of multiple doses of BWC0977 in healthy people
This study tests an experimental antibiotic called BWC0977 to see if it is safe and well-tolerated when given as single and multiple doses. It is for healthy volunteers to understand how the drug behaves in the body before moving to patient trials.
Melbourne, VictoriaAges 18–55 - NCT07024160RecruitingPhase 1
First-in-human study of MT1011 injection in healthy volunteers
This trial tests a new medicine called MT1011 given as an injection. Researchers want to see how safe it is and how the body handles it. Healthy people can join to help find the right dose for future studies.
Beijing, Beijing MunicipalityAges 18–45 - NCT07024173RecruitingPhase 3
HRS-8080 versus doctor's choice for advanced breast cancer
This trial tests a new medicine called HRS-8080 for locally advanced or metastatic breast cancer. It compares HRS-8080 with whatever treatment your doctor would normally choose for you.
Guangzhou, GuangdongAges 18–75 - NCT07029945RecruitingPhase 1/Phase 2
Oral BRX011 for advanced dry age-related macular degeneration
This study tests an oral medication called BRX011 taken once daily for geographic atrophy, a progressive form of advanced dry age-related macular degeneration. The goal is to see if it is safe and can help slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT07025018RecruitingPhase 1
Study of HMPL-306 for brain tumors with IDH mutations
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT07016152RecruitingPhase 1
A study of a Klebsiella vaccine for healthy adults
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
TaipeiAges 18–50 - NCT06827717RecruitingPhase 2
Liposomal irinotecan combo for advanced Ewing sarcoma
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT07007910RecruitingPhase 1
Study of HSK46575 for advanced prostate cancer
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Chengdu, SichuanAges 18 years+ - NCT07007988RecruitingPhase 1
SIM0388 for fluid buildup in the abdomen from cancer
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.